Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Review Article

PBS. 2016; 6(4): 242-55

An updated clozapine treatment guide against clozaphobic attitudes

Mesut Çetin, Samet Köse.

In recent years, clozapine-related publications are gradually increasing. Despite all the new generation of antipsychotics, one-third of patients with scizophrenia are still treatment-resistant. Clozapine is a unique and gold standard antipsychotics with FDA approval for treatment-resistant schizophrenia cases following failure with antipsyhotics from two separate groups with sufficient doses for at least six weeks duration and also preventing suicidal behavior in patients with schizophrenia and schizoaffective disorder. While at least 30% of schizophrenia patients are treatment- resistant and suicide rate is 5%; clozapine, both in Turkey and around the world, is used 10–15 times less in 2–10% of patients. This is not easy to explain rationally like in phobias. Although this cannot be exactly labeled as phobia or clozaphobia, labeling it as a clozaphobic attitude might be appropriate. In our opinion, claiming that prescription of clozapine less than required by the psychiatrists in Turkey due to this clozaphobic attitude is an important public health problem would not be an exaggeration. In addition to clozaphobic attitude, one of the major reasons underlying this attitude is clinicians’ lack of adequate awareness and experience in managing the potential serious adverse events. Clozapine causes major adverse events such as agranulocytosis, myocarditis/ cardiomyopathy, and epileptic seizures along with side effects such as weight gain, constipation, metabolic syndrome which might compromise patient’s health. In addition, daytime sedation, urinary incontinence at night, and hipersalivation can adveresly affect the quality of life of patients. Blood count monitoring for 18 weeks is another reason for reluctant use of clozapine. All these side effects and challenges can be overcome with specific approaches. The FDA promoted a rational use of clozapine with REMS (Risk Evaluation and Mitigation Strategy) program. In this review, updated information about clozapine have been outlined and clinicians were aimed to be informed by the pharmacoeconomics advantages of clozapine and how to overcome the potential adverse events in clozapine use.

Key words: clozapine, clozaphobia, agranulocytosis, myocarditis, antipsychotic treatment, adverse event

Full-text options

Full-text Article

Share this Article

Readers of this article also read the following articles
»Rabeprazole-induced acute interstitial nephritis: A case report
»Dapsone hypersensitivity syndrome - A case report
»Editorial: This Year | March 2016, The Latest News about the Sleep and Hypnosis
»Myasthenia Gravis and anesthesia: a case report
»An educational needs analysis in child and adolescent psychiatry
»Cerebrovascular Events: Correlation with Plaque Type, Velocity Parameters and Multiple Risk Factors
»Schwannoma of lower lip: an unusual case report and review of literature
»Plasma and erythrocyte trace element Profiles of Trypanosoma congolense-infected female and male Cricetomys gambianus, Waterhouse (African Giant Rats)
»Pseudoglucagonoma syndrome secondary to chronic pancreatitis: report of a case and review of the literature
»Surgical management of agenesis of the vulva with atresia ani-et-distal recti in a heifer calf: A case report
»Intramuscular Myxoma [İntramusküler Miksoma]

Progress in Orthopedic Science


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.